Company Filing History:
Years Active: 2014-2017
Title: Rinat Rotem-Yehudar: Innovator in Monoclonal Antibody Therapy
Introduction
Rinat Rotem-Yehudar is a prominent inventor based in Tel Aviv, Israel. He has made significant contributions to the field of monoclonal antibody therapy, particularly in the treatment of cancer patients. With a total of 5 patents to his name, his work is recognized for its innovative approaches to complex medical challenges.
Latest Patents
One of Rinat's latest patents is focused on "Pidilizumab monoclonal antibody therapy following stem cell transplantation." This invention outlines methods for treating specific populations of cancer patients, particularly those who have undergone stem cell transplantation and have been classified as positive by pre-transplant metabolic imaging. The therapy involves administering a therapeutically effective amount of pidilizumab monoclonal antibody to the subject.
Another notable patent is for "Variants of humanized immunomodulatory monoclonal antibodies." This invention relates to humanized monoclonal antibodies and pharmaceutical compositions that include them. It aims to treat a variety of indications, especially cancer and immunodeficiency disorders. The invention provides modified antibodies or fragments with specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1.
Career Highlights
Rinat Rotem-Yehudar is associated with Curetech Ltd., a company that focuses on developing innovative therapies. His work at Curetech has positioned him as a key player in the advancement of monoclonal antibody treatments. His contributions have been instrumental in pushing the boundaries of what is possible in cancer therapy.
Collaborations
Rinat has collaborated with notable colleagues, including Michael Schickler and Galina Rodionov. These collaborations have fostered an environment of innovation and have led to significant advancements in their respective fields.
Conclusion
Rinat Rotem-Yehudar's work in monoclonal antibody therapy exemplifies the impact of innovative thinking in medicine. His patents and collaborations highlight his commitment to improving treatment options for cancer patients. Through his efforts, he continues to contribute to the advancement of medical science and patient care.